# BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)

> **NCT00979576** · PHASE1 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 19 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** BIBF 1120 M + Pemetrexed
- **DRUG:** BIBF 1120 H + Pemetrexed
- **DRUG:** BIBF 1120 RD + Pemetrexed
- **DRUG:** BIBF 1120 L + Pemetrexed
- **DRUG:** BIBF 1120 Placebo + Pemetrexed

## Key facts

- **NCT ID:** NCT00979576
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-10-16
- **Primary completion:** 2015-02-16
- **Final completion:** 2015-02-16
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00979576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00979576, "BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00979576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*